Market Intelligence, Clinical Progress, and High-Purity Reagents for Leukemia and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD1c drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD1c Heterodimer (co-expressed with B2M) / ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View CD1C Products |
| Gene Delivery | CD1c Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based binding assays. |
View CD1C Products |
| Benchmark Ab | Anti-CD1c Recombinant Antibody Recombinant positive control derived from benchmark clones. |
View CD1C Products |
| Validator | CD1c siRNA Set For knockdown verification in functional assays. |
View CD1C Products |
| Related Target A | B2M Essential beta-2 microglobulin subunit required for stable CD1c heterodimer folding and surface expression. |
View B2M Products |
| Related Target B | CD1d Homologous lipid-presenting molecule used for counter-screening to ensure specificity. |
View CD1D Products |
| Related Target C | CD1a Family member used in selectivity panels to rule out off-target binding. |
View CD1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent binding (B2M association) | HEK293 co-expressed CD1c/B2M heterodimer preserving native structural epitopes. |
| Subfamily counter screening (CD1a, CD1b, CD1d) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD1c R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD1c therapeutics is intensifying, with major players shifting focus from traditional mAbs to CAR-T therapies, bispecific T-cell engagers (BiTEs), and CD1c-restricted T-cell receptor (TCR) therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting CD1c-expressing hematological malignancies (such as AML and T-ALL) and leveraging CD1c+ dendritic cells for cancer vaccines.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T / TCR-T | Academic Institutes, Biotech Startups | T-ALL, AML, Solid Tumors | Cell line construction for Flow Cytometry (Need CD1c Lentivirus) |
| Bispecific Antibodies | Immunotherapy Biotechs | Myeloid Leukemia, Autoimmune Diseases | Heterodimer Validation (Need CD1c/B2M Heterodimer Protein) |
| Monoclonal Antibodies | Oncology Biopharma | Dendritic Cell Targeting, Lymphoma | Affinity & Specificity Screening (Need CD1a/b/d Counter-screen Panel) |